Revlimid Related Clinical Trials
Phase I/II Open-Label, Dose Escalation Study To Determine The Maximum Tolerated Dose And To Evaluate The Safety Profile of Lenalidomide (Revlimid® CC-5013) With Liposomal Doxorubicin In Subjects With Advanced Ovarian and Primary Peritoneal Carcinoma [Terminated]
Phase I Open-Label, Dose Escalation Study To Determine The Maximum Tolerated Dose And To Evaluate The Safety Profile Of Lenalidomide (Revlimid®, CC-5013) With Pemetrexed In Subjects With Advanced Non-Small Cell Lung Cancer [Terminated]
A Study of Revlimid for Treatment of Non-Hodgkin's Lymphoma [Active, not recruiting]
Lenalidomide (Revlimid®, CC-5013) in Subjects With Relapsed or Refractory Indolent Non-Hodgkin’s Lymphoma [Completed]
Lenalidomide (Revlimid) in Chronic Lymphocytic Leukemia (CLL) [Active, not recruiting]
Lenalidomide and Dacarbazine (DTIC) in Patients With Metastatic Melanoma [Completed]
Study of Bortezomib and Revlimid™ for Patients Relapsing or Progressing on Total Therapy II [Completed]
Study of Lenalidomide With Topotecan In Subjects With Advanced Ovarian and Primary Peritoneal Carcinoma [Completed]
A Phase I/II Study of Lenalidomide in Combination With Gemcitabine in Patients With Untreated Advanced Carcinoma of the Pancreas [Terminated]
Efficacy of CC-5013 (Revlimid or Lenalidomide) in Patients With Primary Systemic Amyloidosis [Active, not recruiting]
A Multicenter, Single-Arm, Open-Label, Study to Evaluate the Safety and Efficacy of Single-Agent Lenalidomide (Revlimid, CC-5013) in Subjects With Androgen Independent Prostate Cancer. [Terminated]
A Companion Study for Studies THAL-MM-003, CC-5013-MM-009, and CC-5013-MM-010 for Subjects With Multiple Myeloma [Active, not recruiting]
Melphalan, Prednisone, and CC-5013 (Revlimid) as Induction Therapy in Multiple Myeloma [Completed]
A Study to Evaluate the Single-Agent Lenalidomide in Subjects With Recurrent Non-Small-Cell Lung Cancer [Completed]
Study to Evaluate the Efficacy and Safety of Lenalidomide in the Treatment of Complex Regional Pain Syndrome Type 1 [Active, not recruiting]
Study of the Combination of Lenalidomide and DTIC (Dacarbazine) in Patients With Metastatic Malignant Melanoma Previously Untreated With Systemic Chemotherapy [Active, not recruiting]
Safety and Efficacy of CC-5013 Monotherapy in Subjects With Myelodysplastic Syndromes Associated With a Del (5q) Cytogenetic Abnormality [Active, not recruiting]
A Study of CC-5013 in the Treatment of Complex Regional Pain Syndrome (CRPS)
Safety And Efficacy In Subjects With Relapsed Or Refractory Aggressive Non-Hodgkin’s Lymphoma
Efficacy and Safety Study of CC-5013 Monotherapy in Subjects With Myelodysplastic Syndromes [Completed]
Lenalidomide for Patients With Myelofibrosis (MF) [Active, not recruiting]
CC-5013 With or Without Dexamethasone in Treating Patients With Primary Systemic Amyloidosis [Completed]
Phase II Study of Dexamethasone, Thalidomide and Lenalidomide for Subjects With Relapsed or Refractory Multiple Myeloma [Active, not recruiting]
Study to Evaluate the Efficacy and Safety of Lenalidomide in the Treatment of Painful Lumbar Radiculopathy
A Safety and Efficacy Study to Evaluate AMG 531 Treatment in Subject With Myelodysplastic Syndrome Receiving Revlimid [Recruiting]
Bortezomib in Combination With CC-5013 in Patients With Relapsed/Refractory Multiple Myeloma
Phase II Study of Biaxin, Revlimid, and Dexamethasone for Untreated Multiple Myeloma [Active, not recruiting]
CC-5013 Plus Dexamethasone Versus Dexamethasone Alone in Previously Treated Subjects With Multiple Myeloma
A Study of CC-5013 Plus Dexamethasone Versus Dexamethasone Alone in Previously Treated Subjects With Multiple Myeloma
Lenalidomide and Docetaxel in Treating Patients With Advanced Solid Tumors [Active, not recruiting]
A Study of DVd +/ CC-5013 in Relapsed Refractory Multiple Myeloma (MM) [No longer recruiting]
Safety and Efficacy of Single-Agent CC-5013 in Subjects With Relapsed and Refractory Multiple Myeloma [No longer recruiting]
Study of the Safety and Efficacy of CC-5013 Treatment For Patients With Myelodysplastic Syndrome [No longer recruiting]
Phase 1 Study OF CDC-501 in Patients With Solid Tumors [No longer recruiting]
Revlimid in Patients With Acute Myelogenous Leukemia and Myelodysplastic Syndrome [No longer recruiting]
A Multicentre, Single-Arm, Open-Label Safety Study of Lenalidomide Plus Dexamethasone in Previously Treated Subjects With Multiple Myeloma [Active, not recruiting]
Lenalidomide in Treating Patients With Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma That Did Not Respond to Treatment [Recruiting]
Evaluation of Lenalidomide (REVLIMID®) to Treat Subjects With Cutaneous Lupus Erythematosus (CLE) [Recruiting]
Combination Therapy Using Lenalidomide (Revlimid)- Low Dose Dexamethasone and Rituximab for Treatment of Rituximab-Resistant, Non-Aggressive B-Cell Lymphomas [Recruiting]
Lenalidomide and Prednisone in Treating Patients With Myelofibrosis [Active, not recruiting]
Multi-Center Trial of Revlimid® and Rituximab, for First-Line Treatment of Chronic Lymphocytic Leukemia (CLL) [Recruiting]
A Study of Oral CC-5013 (Lenalidomide; Revlimid) in Myelodysplastic Syndromes [Recruiting]
Lenalidomide (Revlimid®) as Second Line Therapy in Patients With Chronic Graft-Vs-Host Disease (GVHD) [Recruiting]
Dose Escalation Study of Revlimid With Fludarabine-Rituximab for CLL/SLL [Recruiting]
Lenalidomide, Docetaxel, and Carboplatin in Treating Patients With Advanced Solid Tumors [No longer recruiting]
Lenalidomide (Revlimid) for the Treatment of Refractory Cancer Pain [Recruiting]
Lenalidomide in Comb w/Rituximab for Pts w/CD5+/CD20+ Hem Malig Who Relapse/Progress After Rituximab [Recruiting]
Study of 2 Different Doses of Revlimid in Biochemically Relapse Prostate Cancer [Recruiting]
A Study to Compare MPR With MP in Newly Diagnosed Multiple Myeloma Subjects 65 Years Old or Older [Recruiting]
Phase II Study Evaluating Toxicity and Efficacy of Lenalidomide (Revlimid®) in Chemotherapy-NaĂŻve Androgen Independent Prostate Cancer Patients [Recruiting]
Pegylated Liposomal Doxorubicin, Low Freq Dexamethasone & Revlimid (Dd-R) in Newly Diagnosed MM [Recruiting]
Lenalidomide Dose Escalation Combined With Rituximab/Fludarabine in Untreated CLL [Recruiting]
Phase II Study of Lenalidomide for the Treatment of Relapsed or Refractory Hodgkin's Lymphoma [Recruiting]
Irinotecan Plus Lenalidomide in Adult Patients With Recurrent Glioblastoma Multiforme [Recruiting]
Lenalidomide Versus Placebo in Myelodysplastic Syndromes With a Deletion 5q- Abnormality [Recruiting]
Phase I Study of Perifosine + Lenalidomide and Dexamethasone for Patients With Multiple Myeloma [Recruiting]
Lenalidomide Plus Rituximab for Indolent Non-Hodgkin's Lymphoma [Recruiting]
Lenalidomide and Rituximab as Treatment of Chronic Lymphocytic Leukemia [Recruiting]
Lenalidomide in Chronic Lymphocytic Leukemia (CLL) Patients With Residual Disease [Recruiting]
A Study to Evaluate Lenalidomide Combined With Dexamethasone in Relapsed or Refractory Diffuse Large B-Cell Lymphoma [Recruiting]
Combination Study of Revlimid®, Velcade® Dexamethasone and Doxil® (RVDD)for Newly Diagnosed Multiple Myeloma [Recruiting]
A Study to Determine the Efficacy and Safety of Lenalidomide in Patients With Mantle Cell NHL Who Have Relapsed or Progressed After Treatment With Bortezomib or Are Refractory to Bortezomib. The "EMERGE" Trial [Not yet recruiting]
Evaluation of Lenalidomide, Doxorubicin and Dexamethasone (RAD) in Patients With Relapsed or Refractory Multiple Myeloma [Recruiting]
Maintenance Therapy Using Lenalidomide in Myeloma [Recruiting]
Lenalidomide as Initial Treatment of Patients With CLL Age 65 and Older [Recruiting]
Study of Lenalidomide and XRT in Patients With Newly Diagnosed Glioblastoma Multiforme [Recruiting]
Lenalidomide and Dexamethasone With/Without Transplant in Patients With Multiple Myeloma [Recruiting]
CDC-501 Therapy in Relapsed or Refractory Multiple Myeloma [Completed]
Study of Lenalidomide in Previously Untreated, Symptomatic Chronic Lymphocytic Leukemia (CLL) [Recruiting]
Phase II Study of Revlimid®, Oral Cyclophosphamide and Prednisone for Patients With Newly Diagnosed Multiple Myeloma [Recruiting]
Lenalidomide in Treating Young Patients With Recurrent, Progressive, or Refractory CNS Tumors [Recruiting]
Dose-Finding of Lenalidomide as Maintenance in Multiple Myeloma [Not yet recruiting]
Study to Determine Efficacy and Safety of Lenalidomide Plus Low-Dose Dexamethasone Versus Melphalan, Prednisone, Thalidomide in Patients With Previously Untreated Multiple Myeloma [Not yet recruiting]
Lenalidomide in Treating Young Patients With Relapsed or Refractory Solid Tumors or Myelodysplastic Syndromes [Recruiting]
A Dose Escalation Study of Lenalidomide in Relapsed or Refractory B-Cell Chronic Lymphocytic Leukemia [Recruiting]
An Expanded Access Program For Lenalidomide Plus Dexamethasone In Previously Treated Subjects With Multiple Myeloma [Recruiting]
A Study to Evaluate the Efficacy and Safety of Lenalidomide as Maintenance Therapy for Patients With B-Cell CLL Following Second Line Therapy [Recruiting]
REVLIMID® (Lenalidomide) for Therapy of Radioiodine-Unresponsive Papillary and Follicular Thyroid Carcinomas [Recruiting]
Revlimid (Lenalidomide) and Dexamethasone (ReDex) Treatment Versus Observation in Patients With Smoldering Multiple Myeloma With High Risk of Progression [Recruiting]
Phase II Trial of Lenalidomide in Older Patients (> 60 Years) With Untreated AML Without Chromosome 5q Abnormalities [Recruiting]
Lenalidomide and Rituximab in the Treatment of Relapsed Mantle Cell Lymphoma (MCL) and Diffuse Large B-Cell Lymphoma [Recruiting]
Celgene High Risk Multiple Myeloma (MM) Revlimid Induction and Maintenance RX [Recruiting]
Phase 1/2 Study of VELCADE® in Combination With Other Drugs to Treat Previously Untreated Multiple Myeloma Patients [Recruiting]
Bevacizumab, Lenalidomide, and Dexamethasone in Treating Patients With Relapsed or Refractory Stage II or Stage III Multiple Myeloma [Recruiting]
Lenalidomide and Melphalan in Treating Patients With Previously Untreated Multiple Myeloma [Active, not recruiting]
Cyclophosphamide, Lenalidomide and Dexamethasone (CLD) for Previously Treated Patients With AL Amyloidosis [Recruiting]
Vorinostat (MK0683, SAHA) + Revlimid + Dexamethasone in Multiple Myeloma [Recruiting]
Study to Compare the Efficacy and Safety of CC-5013 Vs. Placebo in Subjects With Metastatic Malignant Melanoma. [Completed]
Dasatinib in Combination With Revlimid (and Dexamethasone) [Recruiting]
Lenalidomide in High-Risk MDS and AML With Del(5q) or Monosomy 5 [Recruiting]
A Phase II Study of Continuous Versus Syncopated Dosing of CC-5013 for the Treatment of Refractory Multiple Myeloma [Completed]
Lenalidomide in Acute Leukemias and Chronic Lymphocytic Leukemia. [Recruiting]
Lenalidomide and Recombinant Human Stem Cell Factor for Treatment of Myelodysplasia [Recruiting]
CC-5013 in Treating Patients With Transfusion-Dependent Low-Risk or Intermediate-Risk Myelodysplastic Syndrome [No longer recruiting]
Combination of Lenalidomide and Autologous Mature Dendritic Cells Pulsed With KRN7000 in Myeloma [Not yet recruiting]
Lenalidomide and Azacitidine in Treating Patients With Advanced Myelodysplastic Syndromes [Recruiting]
Lenalidomide and Vaccine Therapy in Treating Patients With Relapsed or Refractory Multiple Myeloma [Recruiting]
Study of SGN-40, Lenalidomide, and Dexamethasone in Patients With Multiple Myeloma [Recruiting]
CC-5013 in Treating Patients With Red Blood Cell Transfusion-Dependent Myelodysplastic Syndromes and a Cytogenetic Abnormality [No longer recruiting]
A Phase 1 Dose Escalating Trial of Bortezomib in Combination With Lenalidomide in Patients With Myelodysplasia [Recruiting]
Lenalidomide in Combination With Melphalan and Dexamethasone in Newly-Diagnosed Light-Chain (AL)-Amyloidosis [Recruiting]
|
